TRAVERE THERAPEUTICS IRELAND LIMITED

Travere Therapeutics Ireland Limited is a biopharmaceutical company dedicated to discovering, developing and delivering life-changing medicines for people living with rare diseases. Driven by the experiences of patients, the firm focuses its scientific expertise on rare kidney and metabolic disorders, aiming to set new standards of care and bring tangible hope to those affected.

The company's pipeline targets four therapeutic areas: classical homocystinuria, cystinuria, focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. By advancing innovative treatments such as sparsentan (FILSPARI®) and other investigational candidates, Travere seeks to address unmet medical needs and accelerate the availability of effective therapies. In addition to its research endeavours, Travere shares "Rare Life" stories that celebrate the courage and resilience of patients and their families, reinforcing its patient-centred ethos.

Through a blend of scientific rigour and personal commitment, Travere Therapeutics strives to transform the rare-disease landscape, delivering hope and improved outcomes for patients across Ireland and beyond.